Silence Therapeutics plc (Nasdaq: SLN) has priced an upsized $175 million underwritten public offering only days after reporting positive topline Phase 2 SANRECO results for divesiran in polycythemia vera. The clinical-stage biotechnology company will sell 12,962,963 American Depositary Shares at $13.50 each, with every ADS representing three ordinary shares, while underwriters have a 30-day option to purchase another 1,944,444 ADSs.
The financing materially changes the company’s capital position at a strategically important point in divesiran’s development. Silence Therapeutics reported $72.1 million of cash and cash equivalents at June 30, 2026 and had already said that existing resources were expected to fund operations into 2028. Adding $175 million of gross proceeds would take a simple pro forma cash calculation to roughly $247 million before underwriting costs, offering expenses and spending since the end of June.
The timing matters as much as the size. Silence Therapeutics disclosed positive Phase 2 SANRECO topline results on August 10 and said it anticipates initiating a Phase 3 polycythemia vera trial of divesiran in the first half of 2027. The company then launched a $150 million offering before pricing the transaction at $175 million, a 16.7% increase from the initially proposed amount.
That sequence effectively moves Silence Therapeutics from one financing question to another. Before the raise, investors could reasonably ask whether a company with $72.1 million of cash could comfortably absorb the cost escalation associated with late-stage development. After the financing, the more important question becomes how efficiently the company converts its expanded balance sheet and encouraging Phase 2 dataset into a Phase 3 programme capable of supporting a future regulatory application.
What does the upsized $175 million offering change for Silence Therapeutics?
The immediate effect is a substantial reduction in near-term financing pressure. Silence Therapeutics said in its second-quarter filing that its June 30 cash position was already expected to support forecast operating and capital expenditure requirements into 2028. That forecast was made before the $175 million offering, meaning the new capital is being raised from a considerably stronger starting position than would be typical for a biotechnology company facing an imminent cash runway problem.
The new financing is also large relative to the company’s recent spending rate. Silence Therapeutics reported a net operating cash outflow of $14.1 million for the first six months of 2026, down from $34.1 million in the comparable period of 2025. Research and development expenses fell to $18.3 million during the first half as spending associated with zerlasiran Phase 3 readiness declined.
That historical burn rate should not be projected mechanically into the future. A pivotal programme can require meaningfully greater expenditure than a Phase 2 study, particularly as clinical site numbers, patient recruitment, manufacturing, regulatory work and supporting development activities expand. Silence Therapeutics itself has warned that research and development and administrative costs are expected to rise as it conducts clinical trials and pursues potential marketing approvals.
This is why the raise is better understood as strategic capital for the next development stage rather than simply an extension of the existing runway. Even before accounting for any exercise of the underwriters’ option, the gross proceeds are approximately 2.4 times the company’s June 30 cash balance.
How much dilution could the Silence Therapeutics offering create?
The financing comes with significant equity dilution, although the scale needs to be measured carefully because Silence Therapeutics ADSs each represent three ordinary shares.
The base offering of 12,962,963 ADSs corresponds to approximately 38.89 million ordinary shares. Silence Therapeutics had 141,739,180 ordinary shares outstanding at June 30, equivalent to approximately 47.25 million ADSs. On that reference base, the offering would increase the ordinary share count by about 27.4%, before considering subsequent share activity or the underwriters’ option.
Viewed as ownership dilution rather than share-count growth, the calculation is slightly different. Adding roughly 38.89 million new ordinary shares to the June 30 base would create approximately 180.63 million ordinary shares. Existing holders as a group would therefore own about 78.5% of the enlarged share base, implying roughly 21.5% dilution to their proportional ownership if they do not participate.
The potential over-allotment makes the number larger. The additional 1,944,444 ADS option represents approximately 5.83 million more ordinary shares and could generate another approximately $26.25 million of gross proceeds if exercised in full. On the June 30 share count, full exercise would take newly issued ordinary-share equivalents to approximately 44.72 million, representing an increase of roughly 31.6% against the pre-offering base and ownership dilution of approximately 24% for previous shareholders.
That is meaningful dilution. The counterargument is that biotechnology shareholders frequently prefer companies to raise substantial capital after clinical de-risking rather than wait until cash balances become constrained or pivotal programmes are already consuming capital. The economic test will ultimately be whether the capital creates enough additional programme value to compensate for the larger share count.
Why did the SANRECO Phase 2 results change the financing backdrop?
The offering followed a notable clinical catalyst for divesiran, Silence Therapeutics’ wholly owned short interfering RNA candidate targeting TMPRSS6 in polycythemia vera.
The 36-week randomized, double-blind and placebo-controlled portion of Phase 2 SANRECO enrolled 48 phlebotomy-dependent patients. Silence Therapeutics reported that 88% of divesiran-treated patients met the primary response endpoint compared with 19% receiving placebo, producing a placebo-adjusted difference of 69 percentage points and a reported p-value below 0.0001. Response was defined by the absence of phlebotomy and maintenance of hematocrit below 45% during weeks 18 through 36.
The every-six-week group produced a reported response rate of 93.8%, while the every-12-week group achieved 81.3%. Silence Therapeutics also reported a mean 0.2 phlebotomies per patient across divesiran groups during weeks zero through 36 compared with 2.1 for placebo. The company said the study also showed improvements in hematocrit control, iron-related markers and patient-reported outcomes.
Safety remains particularly important because divesiran is manipulating iron availability as a way to control excessive red blood cell production. The company reported no new safety findings in Phase 2, with infrequent and self-limiting injection-site reactions and two investigator-reported Grade 1 anaemia events. Those findings are encouraging, but the disclosure remains topline data from a 48-patient study rather than a complete late-stage safety package. Full Phase 2 results are expected to be presented at a future medical congress.
Silence Therapeutics has used the phrase “potential best-in-class” in discussing divesiran. That positioning should remain a company assessment rather than an established clinical conclusion because SANRECO was not a head-to-head trial against competing investigational or marketed therapies.
Can the new financing support divesiran’s planned Phase 3 programme?
Silence Therapeutics has said it anticipates starting a Phase 3 polycythemia vera trial in the first half of 2027, evaluating the every-12-week divesiran regimen against placebo. The selection of the quarterly schedule is commercially interesting because lower dosing frequency could potentially become part of the therapy’s differentiation if later-stage efficacy, safety and durability support the Phase 2 signal.
The $175 million financing considerably strengthens the company’s ability to reach that point without operating under the same near-term capital constraint implied by its previous cash position. Including June 30 cash, the base offering would produce approximately $247 million of gross pro forma liquidity before transaction costs and subsequent spending. Full exercise of the underwriters’ option could add another approximately $26.25 million.
That does not mean divesiran is now financed all the way through approval or commercialisation. Phase 3 design, enrolment size, study duration, manufacturing requirements and regulatory discussions will determine the actual cost. Silence Therapeutics has not yet generated the pivotal evidence required for marketing authorisation, and successful Phase 2 results do not guarantee that Phase 3 will reproduce the same magnitude of benefit.
There is nevertheless a meaningful difference between entering pivotal development with a narrow runway and entering it with more than $170 million of fresh gross equity capital. The latter gives management greater flexibility around trial execution, manufacturing preparation and the timing of future financing decisions.
What else is Silence Therapeutics funding as its siRNA pipeline expands?
Divesiran may be the clearest near-term development priority, but Silence Therapeutics is not operating as a single-asset company.
The company reported in August that preclinical programmes targeting GPR146 through SLN365 and INHBE through SLN098 were positioned for potential Investigational New Drug filings in 2027. It has also been evaluating the future of SLN312, the ANGPTL3-targeting programme for which AstraZeneca decided not to continue development beyond Phase 1.
These programmes create optionality, but they also create competing demands on capital. One of the most important strategic decisions following the offering will therefore be how aggressively Silence Therapeutics expands internally funded development beyond divesiran while a pivotal polycythemia vera programme is being prepared.
Capital discipline matters because the company’s financial model is still characteristic of a clinical-stage biotechnology business. Silence Therapeutics recorded only $422,000 of collaboration revenue during the first six months of 2026 and a net loss of $27.2 million. Commercial product revenue is not yet available to fund the pipeline internally.
What will determine whether the $175 million raise creates lasting value?
The financing removes one important risk but leaves the central biotechnology risk intact. Silence Therapeutics now appears significantly better funded to execute divesiran’s next development stage, yet the value of the transaction will ultimately depend on whether Phase 2 SANRECO translates into a convincing pivotal dataset.
Several features of the Phase 2 results justify the stronger financing position. The study was randomized, double-blind and placebo-controlled, the primary endpoint was met with a large reported treatment difference, and both investigated dosing schedules showed activity. At the same time, only 48 patients were included, the currently available disclosure is topline, and a substantially larger Phase 3 programme will be required before the efficacy and safety profile can be judged with the confidence expected for a registration-stage therapy.
The financing therefore changes the Silence Therapeutics story without completing it. Before SANRECO, the question was whether divesiran could produce a sufficiently strong controlled Phase 2 signal to justify pivotal development. After SANRECO and the $175 million raise, the focus shifts toward whether the company can design and execute Phase 3, preserve the apparent benefit of the every-12-week regimen, establish a sufficiently mature safety profile and turn its larger cash position into regulatory progress rather than simply a longer runway.
For Silence Therapeutics, that is a materially better problem to have. The balance sheet is stronger and the lead programme has moved forward, but the next value inflection will come from pivotal execution rather than financing itself.
